GURUFOCUS.COM » STOCK LIST » Healthcare » Medical Diagnostics & Research » Diasorin SpA (CHIX:DIAm) » Definitions » Other Operating Expense

Diasorin SpA (CHIX:DIAM) Other Operating Expense : €67 Mil (TTM As of Mar. 2025)


View and export this data going back to 2010. Start your Free Trial

What is Diasorin SpA Other Operating Expense?

Diasorin SpA's Other Operating Expense for the three months ended in Mar. 2025 was €4 Mil. Its Other Operating Expense for the trailing twelve months (TTM) ended in Mar. 2025 was €67 Mil.

Diasorin SpA's quarterly Other Operating Expense increased from Sep. 2024 (€1 Mil) to Dec. 2024 (€40 Mil) but then declined from Dec. 2024 (€40 Mil) to Mar. 2025 (€4 Mil).

Diasorin SpA's annual Other Operating Expense declined from Dec. 2022 (€64 Mil) to Dec. 2023 (€44 Mil) but then increased from Dec. 2023 (€44 Mil) to Dec. 2024 (€49 Mil).


Diasorin SpA Other Operating Expense Historical Data

The historical data trend for Diasorin SpA's Other Operating Expense can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Diasorin SpA Other Operating Expense Chart

Diasorin SpA Annual Data
Trend Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24
Other Operating Expense
Get a 7-Day Free Trial Premium Member Only Premium Member Only 5.85 16.94 63.60 44.26 48.95

Diasorin SpA Quarterly Data
Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25
Other Operating Expense Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 5.00 21.84 1.00 39.95 4.00

Diasorin SpA Other Operating Expense Calculation

GuruFocus uses a standardized financial statement format for all companies. For non-financial companies, GuruFocus lists Selling, General, & Admin. Expense, , Research & Development, and Other Operating Expense under the "Total Operating Expense" section.

Other Operating Expense sometimes includes:
Restructuring, and merger
Acquisition related and other
Litigation settlement charge
Other (too numerous to list)

Some companies can and do choose to report each of these items separately. Yet, there are a variety of Other Operating Expense which are simply too numerous to list.

Other Operating Expense for the trailing twelve months (TTM) ended in Mar. 2025 adds up the quarterly data reported by the company within the most recent 12 months, which was €67 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Diasorin SpA Other Operating Expense Related Terms

Thank you for viewing the detailed overview of Diasorin SpA's Other Operating Expense provided by GuruFocus.com. Please click on the following links to see related term pages.


Diasorin SpA Business Description

Traded in Other Exchanges
Address
Via Crescentino Snc, Saluggia, Vercelli, ITA, 13040
DiaSorin, headquartered in Italy, is a global provider of in vitro diagnostics, or IVD, which refers to testing done on samples taken from the human body, such as blood and tissue. DiaSorin produces and markets testing reagent kits for immunodiagnostics (about 65% of total sales) and molecular diagnostics (about 20%) and has a total installed base of about 9,000 diagnostic systems. Instruments and other revenue contribute about 15% of total sales. DiaSorin's largest market in 2023 was North America, which accounted for 48% of non-covid revenue, followed by Europe (35%) and the Rest of the World (18%).

Diasorin SpA Headlines

No Headlines